Pharmacokinetic monitoring of aminoglycosides in the extended dosing interval era

LaboratoriumsMedizin

Volumn 26, Issue 1-2, 2002, Pages 43-48

  Vinks, Alexander A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Aminoglycosides; Bayes Theory; Nephrotoxicity; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CREATININE; GENTAMICIN; TOBRAMYCIN;

ANTIBIOTIC THERAPY; BAYES THEOREM; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; HUMAN; INDIVIDUALIZATION; NEPHROTOXICITY; NOMOGRAM; OTOTOXICITY; POPULATION MODEL; REVIEW;

EID: 0036194098     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/LabMed.2002.007     Document Type: Review

References (34)

1. Aminoglycosides-50 years on
2. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?
3. Killing and regrowth of bacetria in vitro: A review
4. Pharmacokinetic/Pharmacodynamic parameters: Rationale for antibacterial dosing in mice and men
5. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents
6. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
7. Aminoglycoside adaptive resistance: Importance for effective dosage regimens
8. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval
9. Post-antibiotic effects in experimental infection models: Relationship to in-vitro phenomena and to treatment of infections in man
10. Some international approaches to aminoglycoside monitoring in the extended dosing interval era
11. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?
12. Aminoglycosides
13. A critical reevaluation of the "therapeutic range" of aminoglycosides
14. An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics
15. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients
16. Kinetic model for gentamicin dosing with the use of individual patient parameters
17. Prediction of future serum concentrations with Bayesian fitted pharmacokinetic models: Results with data collected by nurses versus trained pharmacy residents
18. Individualizing drug dosage regimens: Roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control
19. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis
20. Evaluation of six gentamicin nomograms using a bayesian parameter estimation program
21. Commentary: Single daily dose of aminoglycosides is the preferred mode of administration
22. Development of gentamicin population models for ICU and non-ICU patients using a nonparametric algorithm (NPEM)
23. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily
24. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy
25. A suggested approach to once-daily aminoglycoside dosing
26. Implementation of a once-daily aminoglycoside program in a large community-teaching hospital
27. Once-daily aminoglycoside dosing: Impact on requests and costs for therapeutic drug monitoring
28. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis
29. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations
30. Dosage adjustment for ceftazidime in patients with impaired renal function
31. Optimal sampling times for pharmacokinetic experiments
32. Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies
33. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals
34. Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model